Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Santhera Pharmaceuticals : Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy

share with twitter share with LinkedIn share with facebook
09/23/2020 | 10:20am EDT

Pratteln - Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data on the safety, tolerability and efficacy of vamorolone in patients with Duchenne muscular dystrophy (DMD).

These 18-month treatment data extend previously published 24-week treatment data, and show a reduction of corticosteroid-specific side effects and sustained efficacy with vamorolone including clinical improvement through the 18-month follow-up period.

This publication in the journal PLOS Medicine [1] provides peer-reviewed and detailed open-label data in patients with DMD treated for 18 months with vamorolone. A multi-center, open-label, 24-week trial (VBP15-003; [2, 3]) with a total 24-month long-term extension (VBP15-LTE; [4]) was conducted by the Cooperative International Neuromuscular Research Group (CINRG) and evaluated drug-related effects of vamorolone on motor outcomes and corticosteroid-associated safety concerns. This publication covers the 24-week Phase 2a trial (VBP15-003) and the first 12 months of the open-label extension trial (VBP15-LTE) adding up to a total treatment period of 18 months.

'This long-term study showed significant continued clinical improvement of all outcomes measured over an 18-month follow-up period,' said Edward C. Smith, MD, Associate Professor of Pediatrics, Duke University, Durham (North Carolina, USA), clinical investigator and lead-author of the publication. 'Treatment-related efficacy responses with vamorolone were similar to those seen in an external control group with corticosteroid-treated patients. Both 4-stair climb and 10-meter run/walk tests were significantly improved when compared to steroid-naive natural history control subjects.'

'Importantly, we also found that vamorolone did not show stunting of growth seen with deflazacort and prednisone, and vamorolone also showed fewer physician-reported adverse events such as mood disturbance, excessive hair growth, and Cushingoid appearance,' noted Eric Hoffman, PhD, Vice President of Research at ReveraGen BioPharma, Inc. and co-author of the study.

DMD trial participants (4 to

(C) 2020 Electronic News Publishing, source ENP Newswire


share with twitter share with LinkedIn share with facebook
All news about SANTHERA PHARMACEUTICALS HOLDING AG
10/23SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
10/22SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
PU
10/22SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
10/22Santhera Completes Capital Increase for Financing Arrangements
GL
10/22SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
10/06SANTHERA PHARMACEUTICALS : to Discontinue Phase 3 SIDEROS Study and Development ..
PU
10/06SANTHERA PHARMACEUTICALS : to Discontinue Phase 3 SIDEROS Study and Development ..
AQ
10/06SANTHERA PHARMACEUTICALS : to Discontinue Phase 3 SIDEROS Study and Development ..
AQ
10/06Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in ..
GL
09/23SANTHERA PHARMACEUTICALS : Announces Publication of Long-Term Clinical Data with..
AQ
More news
Financials
Sales 2020 14,6 M 16,0 M 16,0 M
Net income 2020 -59,6 M -65,1 M -65,1 M
Net cash 2020 35,0 M 38,3 M 38,3 M
P/E ratio 2020 -0,92x
Yield 2020 -
Capitalization 48,7 M 53,2 M 53,3 M
EV / Sales 2020 0,94x
EV / Sales 2021 -0,07x
Nbr of Employees 113
Free-Float 80,3%
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 6,50 CHF
Last Close Price 3,00 CHF
Spread / Highest target 117%
Spread / Average Target 117%
Spread / Lowest Target 117%
EPS Revisions
Managers
NameTitle
Dario Eklund Chief Executive Officer
Elmar J. Schnee Chairman
Andrew P. Smith Chief Financial Officer
Kristina Sjöblom Nygren Chief Medical Officer, EVP & Head-Development
Thomas Meier Director
Sector and Competitors